DAS181 Mechanism of Action

The Latest Technology for

preventing and treating life-threatening human diseases.

At Ansun, we are committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients.

Company Updates:

  • Ansun is currently working with FDA to plan and implement a Phase 3 clinical trial of DAS181 for the treatment of PIV infection in hospitalized and immunocompromised patients.
  • DAS181 has received both Fast Track and Breakthrough Therapy designations by the U.S. FDA for this indication.
  • Ansun has observed activity of DAS181 against other important respiratory pathogens based on the same host-directed anti-viral mechanism.